Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3355 |
|
Actual shortage: | 217 (6%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 335 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
61 (25%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2017-09-26 | 2017-10-03 | 23533 |
APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2017-12-12 | 2018-01-24 | 32511 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-01-10 | 2018-04-19 | 35536 |
APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2018-03-05 | 2018-08-14 | 41847 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-03-13 | 2018-04-19 | 42669 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-05-02 | 2018-07-25 | 47963 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-08-09 | 2018-09-29 | 57766 |
APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2018-08-27 | 2018-10-19 | 59287 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2019-10-09 | 2019-12-09 | 95821 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2019-12-05 | 2019-12-16 | 100203 |
APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2020-07-23 | 2020-08-07 | 120979 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 40MG | TABLET | Resolved | 2019-12-12 | 2020-01-15 | 101082 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 80MG | TABLET | Resolved | 2019-12-12 | 2020-01-22 | 101088 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 10MG | TABLET | Resolved | 2020-07-08 | 2020-07-13 | 119677 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 40MG | TABLET | Resolved | 2020-07-08 | 2020-07-13 | 119683 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 80MG | TABLET | Resolved | 2020-07-08 | 2020-07-13 | 119687 |
APO-AMLODIPINE-ATORVASTATIN | 5MG 80MG | TABLET | Resolved | 2020-07-08 | 2020-07-13 | 119690 |
APO-AMLODIPINE-ATORVASTATIN | 80MG 5MG | TABLET | Resolved | 2023-07-07 | 2023-09-01 | 197872 |
APO-AMLODIPINE-ATORVASTATIN | 80MG 10MG | TABLET | Resolved | 2023-12-08 | 2024-01-19 | 212940 |
APO-AMLODIPINE-ATORVASTATIN | 10MG 80MG | TABLET | Resolved | 2021-01-29 | 2021-05-26 | 132703 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |